Microparticle-containing oncotic solutions augment in-vitro clot disruption by ultrasound

Yochai Birnbaum, Zaza Iakobishvili, Avital Porter, David Hasdai, Shaul Atar, Robert J. Siegel, Alexander Battler

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Echocardiographic contrast agents enhance blood clot disruption by ultrasound. It has been suggested that the microbubbles add nuclei for the enhancement of cavitation by ultrasound. However, microbubbles are rapidly destroyed by the ultrasound energy. We assessed whether non-gas filled colloidal solutions (hyperoncotic medium molecular hydroxyethyl starch and degraded gelatin polypeptides) will facilitate clot disruption by ultrasound. In two separate experiments human blood clots, 200-400 mg in weight, were weighed and then immersed for 15 seconds in 10 ml normal saline solution containing 0%, 0.1%, 1%, 2%, and 5% of hyperoncotic medium molecular hydroxyethyl starch or 0%, 0.035%, 0.175%, 0.35%, and 0.7% degraded gelatin polypeptides. Clots were randomized to 10 seconds 20 kHz ultrasound or immersion without ultrasound. After treatment, the clots were re-weighed, and the percent difference in weight was calculated. Non-gas filled microparticle-containing solutions such as hyperoncotic medium molecular hydroxyethyl starch and degraded gelatin polypeptides significantly augmented blood clot disruption by ultrasound. The effect is dependent on the colloidal solution concentration with maximal effect achieved with 1% hyperoncotic medium molecular hydroxyethyl starch and 0.35% degraded gelatin polypeptides. Copyright (C) 2000 Elsevier Science Ltd.

Original languageEnglish
Pages (from-to)549-557
Number of pages9
JournalThrombosis Research
Volume98
Issue number6
DOIs
StatePublished - 15 Jun 2000
Externally publishedYes

Keywords

  • Gelatin polypeptides
  • Hydroxyethyl starch
  • Microparticles
  • Reperfusion
  • Thrombolysis
  • Thrombosis
  • Ultrasound

Fingerprint

Dive into the research topics of 'Microparticle-containing oncotic solutions augment in-vitro clot disruption by ultrasound'. Together they form a unique fingerprint.

Cite this